1Espinel-Ingroff A. Related Articles. Clinical relevance of antifungal resistance[J]. Infect Dis Clin North Am, 1997, 11(4): 929-944.
2Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing:. conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole,itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards[J]. Clin Infect Dis, 1997, 24(2): 235-247.
3Lynch ME, Sobel JD, Fidel PL. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis[J]. J Med Vet Mycol, 1996, 34(5): 337-339.
4Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis[J]. Clin Infect Dis, 1992, 14( Suppl 1): S148-153.
5National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts:approved standard. NCCLS document M-27A[S]. Wayne, Pennsylvania,NCCLS, 1997.
